Subgroup

Control Group

(N = 50)

Mean Difference (95% CI)

p-value

Semaglutide

(N = 23)

EBWL at 12 months (pre-surgery)

64.1 ± 16.7%

68.8 ± 22.2%

4.7 (-5.7 to 15.1)

0.3695

EBWL at 12 months (consult)

69.6 ± 13.6%

71.2 ± 20.9%

1.6 (-7.9 to 11.1)

0.7384

Dulaglutide

(N = 13)

EBWL at 12 months (pre-surgery)

60.9 ± 22.0%

68.8 ± 22.2%

7.9 (-5.9 to 21.7)

0.2567

EBWL at 12 months (consult)

64.7 ± 19.2%

71.2 ± 20.9%

6.5 (-6.3 to 19.3)

0.3143

Tirzepatide

(N = 12)

EBWL at 12 months (pre-surgery)

71.2 ± 21.0%

68.8 ± 22.2%

-2.4 (-16.5 to 11.7)

0.7353

EBWL at 12 months (consult)

77.3 ± 19.3%

71.2 ± 20.9%

-6.1 (-19.4 to 7.2)

0.361

Duration ≥ 6

months (N = 24)

EBWL at 12 months (pre-surgery)

61.1 ± 17.6%

68.8 ± 22.2%

7.7 (-2.6 to 18.0)

0.1424

EBWL at 12 months (consult)

66.4 ± 15.8%

71.2 ± 20.9%

4.8 (-4.8 to 14.4)

0.3228

Efficacy dosing^*

(N = 42)

EBWL at 12 months (pre-surgery)

64.2 ± 20.5%

68.8 ± 22.2%

4.6 (-4.3 to 13.5)

0.3081

EBWL at 12 months (consult)

69.4 ± 18.0%

71.2 ± 20.9%

1.8 (-6.4 to 10.0)

0.6624

High dosing^**

(N = 28)

EBWL at 12 months (pre-surgery)

64.1 ± 18.0%

68.8 ± 22.2%

4.7 (-5.1 to 14.5)

0.3416

EBWL at 12 months (consult)

69.8 ± 16.5%

71.2 ± 20.9%

1.4 (-7.7 to 10.5)

0.7613